Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Muss on Determining Treatments for HER2+ Breast Cancer

Hyman B. Muss, MD
Published: Monday, Oct 09, 2017



Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

In the APT trial, patients with HER2-positive breast cancer with smaller node-negative tumors received weekly paclitaxel (Abraxane) and 1 year of trastuzumab (Herceptin). This trial of 400 patients showed 4 relapses with a median follow-up of 6 years. According to Muss, if a patient fits this criteria they should receive this treatment.

If a patient has a more aggressive disease, chemotherapy that omits anthracyclines and regimens that include docetaxel, carboplatin, and trastuzumab should be given.
 


Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

In the APT trial, patients with HER2-positive breast cancer with smaller node-negative tumors received weekly paclitaxel (Abraxane) and 1 year of trastuzumab (Herceptin). This trial of 400 patients showed 4 relapses with a median follow-up of 6 years. According to Muss, if a patient fits this criteria they should receive this treatment.

If a patient has a more aggressive disease, chemotherapy that omits anthracyclines and regimens that include docetaxel, carboplatin, and trastuzumab should be given.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x